The PPARγ Agonist Rosiglitazone Enhances the Radiosensitivity of Human Pancreatic Cancer Cells

References

• WolfgangCL, HermanJM, LaheruDA, et al. Recent progress in Pancreatic Cancer. CA Cancer J Clin. 2013;63(5):318–348. doi:10.3322/caac.2119023856911
   PubMed Web of Science ®Google Scholar
• SiegelRL, MillerKD, JemalA. Cancer statistics. CA Cancer J Clin. 2017;67(1):7–30. doi:10.3322/caac.2138728055103
   PubMed Web of Science ®Google Scholar
• LinQJ, FengY, ChenJ, et al. Current status and progress of pancreatic cancer in China. World J Gastroenterol. 2015;21(26):7988–8003. doi:10.3748/wjg.v21.i26.798826185370
   PubMed Web of Science ®Google Scholar
• RossiML, RehmanAA, GondiCS. Therapeutic options for the management of pancreatic cancer. World J Gastroenterol. 2014;20(32):11142–11159. doi:10.3748/wjg.v20.i32.1114225170201
   PubMed Web of Science ®Google Scholar
• SharmaRA, PlummerR, StockJK, et al. Clinical development of new drug-radiotherapy combinations. Nat Rev Clin Oncol. 2016;13(10):627–642. doi:10.1038/nrclinonc.2016.7927245279
   PubMed Web of Science ®Google Scholar
• AbbottBD. Review of the expression of peroxisome proliferator-activated receptors alpha (PPARα), beta (PPARβ), and gamma (PPARγ) in rodent and human development. ReprodToxicol. 2009;27(34):246–257.
   Google Scholar
• YoussefJ, BadrM. Peroxisome proliferator-activated receptors and cancer: challenges and opportunities. Br J Pharmacol. 2011;164(1):68–82. doi:10.1111/j.1476-5381.2011.01383.x21449912
   PubMed Web of Science ®Google Scholar
• SchmidtMV, BrüneB, Von KnethenA. The nuclear hormone receptor PPARγ as a therapeutic target in major diseases. Scientific World J. 2010;10:2181–2197. doi:10.1100/tsw.2010.213
   Web of Science ®Google Scholar
• TeresiRE, WaiteKA. PPARγ, PTEN, and the fight against cancer. PPAR Res. 2008;932632.19096712
   PubMed Web of Science ®Google Scholar
• ChoES, KimMK, SonYO, et al. The effects of rosiglitazone on osteoblastic differentiation, osteoclast formation and bone resorption. Mol Cells. 2012;33(2):173–181. doi:10.1007/s10059-012-2240-z22286232
   PubMed Web of Science ®Google Scholar
• LuoY, YinW, SignoreAP, et al. Neuroprotection against focal ischemic brain injury by the peroxisome proliferator-activated receptor-γ agonist rosiglitazone. J Neurochem. 2006;97(2):435–448. doi:10.1111/j.1471-4159.2006.03758.x16539667
   PubMed Web of Science ®Google Scholar
• LinCF, YoungKC, BaiCH, et al. Rosiglitazone regulates anti-inflammation and growth inhibition via PTEN. Biomed Res Int. 2014;2014:787924.24757676
   PubMed Web of Science ®Google Scholar
• BonofiglioD, CioneE, QiH. Combined low doses of PPARγ and RXR ligands trigger an intrinsic apoptotic pathway in human breast cancer cells. Am J Pathol. 2009;175(3):1270–1280. doi:10.2353/ajpath.2009.08107819644018
   PubMed Web of Science ®Google Scholar
• ZhangW, WuN, LiZ, WangL, JinJ, ZhaXL. PPAR gamma activator rosiglitazone inhibits cell migration via upregulation of PTEN in human hepatocarcinoma cell line BEL-7404. Cancer Biol Ther. 2006;5(8):1008–1014. doi:10.4161/cbt.5.8.288716775433
   PubMed Web of Science ®Google Scholar
• HanSW, RomanJ. Rosiglitazone suppresses human lung carcinoma cell growth through PPARγ-dependent and PPARγ-independent signal pathways. Mol Cancer Ther. 2006;5(2):430–437. doi:10.1158/1535-7163.MCT-05-034716505118
   PubMed Web of Science ®Google Scholar
• Krieger-HinckN, SchumacherU, MüllerA, ValentinerU. The effect of the PPAR-gamma agonist rosiglitazone on neuroblastoma SK-N-SH cells in a metastatic xenograft mouse model. Oncol Res. 2010;8(8):387–393.
   Web of Science ®Google Scholar
• XueJ, ZhuW, SongJ, et al. Activation of PPARα by clofibrate sensitizes pancreatic cancer cells to radiation through the Wnt/β-catenin pathway. Oncogene. 2018;37(7):953–962. doi:10.1038/onc.2017.40129059162
   PubMed Web of Science ®Google Scholar
• SongJ, ShenW, XueJ, et al. Fenofibrate enhances the radiosensitivity of human pancreatic cancer cells in vitro and in vivo. Int J Clin Exp Med. 2017;10(11):15168–15177.
   Web of Science ®Google Scholar
• Guide for the Care and Use of Laboratory Animals. National Research Council. 8th Edition Washington DC: The NationalAcademies Press; 2011.
   Google Scholar
• XuC, ChenY, ZhangH, et al. Integrated microRNA-mRNA analyses reveal OPLL specific microRNA regulatory network using high-throughput sequencing. Sci Rep. 2016;6:21580. doi:10.1038/srep2158026868491
   PubMed Web of Science ®Google Scholar
• SpringE, HolmbergP. Evaluation of experimental irradiation fractionation with the single-hit, multi-target model. Acta Radiol Ther Phys Biol. 1968;7(4):297–306. doi:10.3109/028418668091332035709605
   PubMed Web of Science ®Google Scholar
• BaskarR, LeeKA, YeoR, YeohKW. Cancer and radiation therapy: current advances and future directions. Int J Med Sci. 2012;9(3):193–199. doi:10.7150/ijms.363522408567
   PubMed Web of Science ®Google Scholar
• VignardJ, MireyG, SallesB. Ionizing-radiation induced DNA double-strand breaks: A direct and indirect lighting up. Radiother Oncol. 2013;108(3):362–369. doi:10.1016/j.radonc.2013.06.01323849169
   PubMed Web of Science ®Google Scholar
• SarrafP, MuellerE, JonesD, et al. Differentiation and reversal of malignant changes in colon cancer through PPARγ. Nat Med. 1998;4(9):1046–1052. doi:10.1038/20309734398
   PubMed Web of Science ®Google Scholar
• ChangTH, SzaboE. Induction of differentiation and apoptosis by ligands of peroxisome proliferator-activated receptor γ in non-small cell lung cancer. Cancer Res. 2000;60(4):1129–1138.10706135
   PubMed Web of Science ®Google Scholar
• OhtaK, EndoT, HaraguchiK, HershmanJM, OnayaT. Ligands for peroxisome proliferator-activated receptor γ inhibit growth and induce apoptosis of human papillary thyroid carcinoma cells. J Clin Endocrinol Metab. 2001;86(5):2170–2177. doi:10.1210/jcem.86.5.749311344222
   PubMed Web of Science ®Google Scholar
• MotomuraW, OkumuraT, TakahashiN, ObaraT, KohgoY. Activation of peroxisome proliferator-activated receptor γ by troglitazone inhibits cell growth through the increase of p27Kip1 in human Pancreatic carcinoma cells. Cancer Res. 2000;60(19):5558–5564.11034103
   PubMed Web of Science ®Google Scholar
• DaiY, QiaoL, ChanKW, et al. Loss of XIAP sensitizes rosiglitazone-induced growth inhibition of colon cancer in vivo. Int J Cancer. 2008;122(12):2858–2863. doi:10.1002/ijc.2344318351648
   PubMed Web of Science ®Google Scholar
• QinL, GongC, ChenAM, et al. Peroxisome proliferator-activated receptor γ agonist rosiglitazone inhibits migration and invasion of prostate cancer cells through inhibition of the CXCR4/CXCL12 axis. Mol Med Rep. 2014;10(2):695–700. doi:10.3892/mmr.2014.223224842333
   PubMed Web of Science ®Google Scholar
• ChiuSJ, HsaioCH, TsengHH, et al. Rosiglitazone enhances the radiosensitivity of p53-mutant HT-29 human colorectal cancer cells. Biochem Biophys Res Commun. 2010;394(3):774–779. doi:10.1016/j.bbrc.2010.03.06820227390
   PubMed Web of Science ®Google Scholar
• AnZ, YuJR, ParkWY. Rosiglitazone enhances radiosensitivity by inhibiting repair of DNA damage in cervical cancer cells. Radiat Environ Biophys. 2017;56(1):89–98. doi:10.1007/s00411-016-0679-928184999
   PubMed Web of Science ®Google Scholar
• CerboneA, ToaldoC, MinelliR, et al. Rosiglitazone and AS601245 decrease cell adhesion and migration through modulation of specific gene expression in human colon cancer cells. PLoS One. 2012;7(6):e40149. doi:10.1371/journal.pone.004014922761953
   PubMed Web of Science ®Google Scholar
• RojasV, LaimeD. Rosiglitazone role in the expression of KLF6 Caco-2 colon cancer cells. Int J Morphol. 2017;35(1):259–264. doi:10.4067/S0717-95022017000100042
   Web of Science ®Google Scholar
• TangZ, ShenQ, XieH, et al. Elevated expression of FABP3 and FABP4 cooperatively correlates with poor prognosis in non-small cell lung cancer (NSCLC). Oncotarget. 2016;7(29):46253–46262. doi:10.18632/oncotarget.1008627323829
   PubMedGoogle Scholar
• ZhongCQ, ZhangXP, MaN, et al. FABP4 suppresses proliferation and invasion of hepatocellular carcinoma cells and predicts a poor prognosis for hepatocellular carcinoma. Cancer Med. 2018;7(6):2629–2640. doi:10.1002/cam4.151129733540
   PubMed Web of Science ®Google Scholar
• TanNS, ShawNS, VinckenboschN, et al. Selective cooperation between fatty acid binding proteins and peroxisome proliferator-activated receptors in regulating transcription. Mol Cell Biol. 2002;22(14):5114–5127. doi:10.1128/MCB.22.14.5114-5127.200212077340
   PubMed Web of Science ®Google Scholar
• OlokpaE, BoldenA, StewartLV. The androgen receptor regulates PPARγ expression and activity in human Prostate Cancer cells. J Cell Physiol. 2016;231(12):2664–2672. doi:10.1002/jcp.2536826945682
   PubMed Web of Science ®Google Scholar
• TaylorKM, MorganHE, SmartK, et al. The emerging role of the LIV-1 subfamily of zinc transporters in breast cancer. Mol Med. 2007;13(78):396–406. doi:10.2119/2007-00040.Taylor17673939
   PubMed Web of Science ®Google Scholar
• TaylorKM, HiscoxS, NicholsonRI, HogstrandC, KilleP. Protein kinase CK2 triggers cytosolic zinc signaling pathways by phosphorylation of zinc channel ZIP7. Sci Signal. 2012;5(210):ra11. doi:10.1126/scisignal.200258522317921
   PubMed Web of Science ®Google Scholar
• WeiY, DongJ, LiF, WeiZ, TianY. Knockdown of SLC39A7 suppresses cell proliferation, migration and invasion in cervical cancer. Excli J. 2017;16:1165–1176. doi:10.17179/excli2017-69029285013
   PubMed Web of Science ®Google Scholar